9.2 Surgical Interventions & Hypoglossal Nerve Stimulation

9.2 Surgical Interventions & Hypoglossal Nerve Stimulation

Quick Answer: Surgical interventions for obstructive sleep apnea (OSA) aim to alleviate site-specific upper airway collapse, reduce critical closing pressure (Pcrit), and improve therapeutic tolerance. While traditional soft tissue surgeries such as uvulopalatopharyngoplasty (UPPP) yield modest long-term success (~40–50% by Sher criteria), skeletal procedures like maxillomandibular advancement (MMA) achieve high success (~85–90%) in severe refractory OSA. Tonsillectomy and adenoidectomy (T&A) remains the first-line gold standard for pediatric OSA. Hypoglossal nerve stimulation (HNS) provides an advanced neurostimulation option by synchronizing mild electrical pulses to the medial branch of CN XII with inspiration, selectively activating the genioglossus to advance the tongue. Current FDA labeling for Inspire covers PAP-intolerant adults with moderate-to-severe OSA (AHI 15–100), BMI up to 40 kg/m², central and mixed apneas under 25% of events, and no complete concentric collapse (CCC) at the soft palate on drug-induced sleep endoscopy (DISE); many insurers still use narrower criteria such as AHI 15–65 and BMI under 35.

When positive airway pressure therapy fails or is not tolerated, surgical evaluation offers targeted anatomical and neurostimulatory pathways to stabilize the collapsible upper airway.

Principles of Upper Airway Surgical Interventions

The human pharynx is a collapsible muscular tube lacking rigid cartilaginous support, susceptible to dynamic collapse during sleep at multiple anatomical levels:

1. Velopharynx / Retropalatal: Soft palate, uvula, and posterior pharyngeal wall.
2. Oropharynx: Palatine tonsils and lateral pharyngeal walls.
3. Hypopharynx / Retroglossal: Base of the tongue, epiglottis, and lingual tonsils.
4. Nasal Cavity: Nasal septum, inferior turbinates, and internal nasal valves.

When to Refer: AASM 2021 Guideline

The AASM's 2021 guideline on surgical referral recommends that clinicians discuss referral to a sleep surgeon with adults who have OSA and a BMI under 40 kg/m² and are intolerant of or unwilling to use PAP. It suggests surgical referral for adults with persistently inadequate PAP adherence because of pressure-related side effects, and suggests discussing referral to a bariatric surgeon for adults with OSA and a BMI of 35 or higher who are intolerant of or unwilling to use PAP. The CCSH makes sure that conversation happens and the referral is completed.

The Sher Criteria for Surgical Success

In sleep surgery literature and clinical practice, the standardized metric for evaluating surgical efficacy is the Sher criteria:

• Definition of Success: A postoperative reduction in baseline AHI of at least 50% combined with a residual postoperative AHI of less than 20 events/hour.
• Definition of Cure: Normalization of sleep respiration, defined as a residual AHI less than 5 events/hour.

Drug-Induced Sleep Endoscopy (DISE)

Because awake upper airway examination does not reflect neuromuscular hypotonia during sleep, Drug-Induced Sleep Endoscopy (DISE) is performed under controlled intravenous sedation (typically propofol or dexmedetomidine). A flexible fiberoptic nasopharyngoscope visualizes the dynamic collapse patterns using the standardized VOTE classification:

• V — Velum (soft palate and uvula): anteroposterior (AP), lateral, or concentric collapse.
• O — Oropharynx (palatine tonsils and lateral pharyngeal walls): lateral collapse.
• T — Tongue base (retroglossal space): anteroposterior collapse.
• E — Epiglottis: anteroposterior (trapdoor) or lateral (curled) collapse.

Soft Tissue Surgical Procedures

Uvulopalatopharyngoplasty (UPPP)

UPPP was historically the most common surgical procedure performed for adult OSA:

• Technique: Resection of the palatine tonsils, the uvula, and redundant posterior velar tissue, with suturing of the anterior and posterior tonsillar pillars to widen the retropalatal airway.
• Efficacy: In unselected OSA populations, UPPP achieves a success rate of only 40% to 50% by Sher criteria. In patients with isolated retropalatal collapse and prominent Friedman Stage I palatine tonsils, success rates improve; however, in unselected patients with multilevel or tongue-base collapse, failure rates are high.
• Complications & Morbidity: Severe postoperative odynophagia, risk of velopharyngeal insufficiency (VPI, nasal regurgitation of liquids), nasopharyngeal stenosis, chronic globus sensation, and altered taste (dysgeusia).

Pediatric Tonsillectomy & Adenoidectomy (T&A)

In pediatric obstructive sleep apnea, adenotonsillar hypertrophy represents the primary anatomical etiology:

• First-Line Standard: Adenotonsillectomy is the universally recognized first-line gold standard for pediatric OSA.
• Efficacy: Achieves clinical cure (AHI less than 1 event/hour) in approximately 70% to 85% of non-obese pediatric patients with adenotonsillar enlargement.

Lingual Tonsillectomy & Midline Glossectomy

For patients with demonstrated retroglossal obstruction on DISE:

• Lingual Tonsillectomy: Endoscopic or robotic (TORS) resection of hypertrophic lingual lymphoid tissue along the posterior third of the tongue.
• Submucosal Midline Glossectomy: Central wedge excision or radiofrequency ablation of tongue-base volume to enlarge the hypopharyngeal lumen.

Skeletal Surgical Modifications

Maxillomandibular Advancement (MMA)

Maxillomandibular advancement represents the most efficacious non-PAP surgical procedure for severe, refractory OSA:

• Surgical Technique: A Le Fort I osteotomy of the maxilla and bilateral sagittal split osteotomy (BSSO) of the mandible are executed simultaneously. Both the upper and lower jaws are advanced anteriorly by 10 to 12 mm and rigidly fixated with titanium miniplates and screws.
• Biomechanical Mechanism: Anterior repositioning of the skeletal framework stretches and advances all attached velopharyngeal and suprahyoid musculature—including the genioglossus, geniohyoid, tensor veli palatini, and palatopharyngeus—dramatically enlarging both the retropalatal and retroglossal airway lumens and drastically decreasing pharyngeal collapsibility.
• Clinical Efficacy: Achieves a Sher success rate of 85% to 90%, with approximately 50% of patients achieving complete cure (AHI less than 5 events/hour). It is considered the definitive surgical intervention for severe OSA refractory to other treatments.
• Morbidity & Recovery: Substantial surgical morbidity, including 1 to 3 days of hospitalization, intermaxillary fixation with elastics, neurosensory paresthesia of the inferior alveolar nerve (chin and lower lip numbness, often prolonged), temporary chewing limitations, alteration of facial profile, and requirements for pre- and post-surgical orthodontics.

Surgically Assisted Rapid Palatal Expansion (SARPE) & DOME

In patients with severe transverse maxillary deficiency, high-arched narrow hard palates, and elevated nasal resistance, distraction osteogenesis maxillary expansion (DOME) or SARPE expands the midpalatal suture, increasing nasal floor width and anterior oral cavity volume.

Adjunctive Nasal Surgery

Nasal procedures include septoplasty, submucosal resection or radiofrequency ablation of inferior turbinates, and functional rhinoplasty (nasal valve repair):

• Clinical Purpose: Alleviate fixed anterior nasal resistance, eliminate mandatory nocturnal mouth breathing, and resolve nasal congestion.
• Impact on OSA (The CCSH Teaching Point): Isolated nasal surgery rarely cures OSA and produces minimal standalone reduction in AHI (typically less than 10% AHI reduction). However, nasal surgery is highly valuable because it significantly improves PAP adherence, lowers required therapeutic PAP pressure settings, and improves daytime nasal breathing.

Hypoglossal Nerve Stimulation (HNS / Inspire Therapy)

Hypoglossal nerve stimulation is a breakthrough FDA-approved implantable neurostimulation therapy that restores pharyngeal muscle tone synchronously with breathing.

Neurostimulation Mechanism

Earlier Inspire systems have three implanted components, listed below. The Inspire V system (FDA approved in 2024) senses breathing inside the generator and no longer needs the separate sensing lead.

1. Implantable Pulse Generator (IPG): Positioned in an infraclavicular subcutaneous pocket on the right side of the chest.
2. Respiratory Sensing Lead: Placed between the internal and external intercostal muscles (typically 4th to 6th intercostal space) to continuously detect changes in thoracic pressure indicating inspiratory effort.
3. Stimulation Lead: Wrapped with a self-sizing cuff around the medial division of the distal right hypoglossal nerve (Cranial Nerve XII). The medial branch specifically innervates the genioglossus (protrusor) and geniohyoid muscles, while sparing the lateral branch that innervates the styloglossus and hyoglossus (retractor muscles). Synchronized mild electrical pulses contract the genioglossus during inspiration, protruding the tongue forward and opening the retroglossal airway while indirectly stabilizing the palate via palatoglossal coupling.

Candidacy Criteria (FDA Labeling and Payer Rules)

Inspire's FDA labeling (expanded in June 2023) and typical payer policies include:

1. Severity: moderate-to-severe OSA with AHI 15–100 under the 2023 label. Many payers, including Medicare contractors, still apply the older AHI 15–65 range.
2. PAP failure or intolerance: documented failure or inability to tolerate PAP despite reasonable efforts such as mask refitting, comfort settings and adherence support.
3. Body mass index: the 2023 label raised the recommended BMI limit to 40 kg/m²; many payers still require a BMI under 35. Excess neck and tongue fat blunts the effect of tongue protrusion.
4. No complete concentric collapse (CCC) at the velum on drug-induced sleep endoscopy (DISE): circumferential palatal collapse does not open with tongue advancement, while anteroposterior collapse is favorable.
5. Central and mixed apneas under 25% of the total AHI.
6. Age: adults 22 and older; ages 18–21 with moderate-to-severe OSA; and adolescents 13–18 with Down syndrome and severe OSA (AHI above 10 and below 50) who cannot use PAP and are not helped by adenotonsillectomy.

A second system, Nyxoah's Genio (FDA approved in August 2025 for AHI 15–65), stimulates the hypoglossal nerves on both sides through a battery-free implant powered by an external unit worn during sleep.

Post-Operative Management & Titration Protocol

• Healing Phase (Weeks 0–4): The device remains powered OFF for 4 to 6 weeks to allow surgical incision healing, lead cuff tissue encapsulation, and resolution of postoperative edema.
• Activation Visit (Week 4–6): The clinician activates the IPG, establishes sensory, motor, and discomfort stimulation thresholds, and programs a functional baseline amplitude. The patient is trained on the handheld remote control (turning the device on at bedtime, using the pause feature for nocturnal awakenings, and managing small amplitude adjustments).
• Acclimatization (Weeks 6–10): The patient uses the device nightly, gradually acclimating to tongue advancement.
• In-Laboratory Titration Polysomnography (Month 3): An overnight polysomnogram is conducted to titrate stimulation parameters (amplitude, electrode configuration, pulse width, frequency) across all sleep stages (including REM) and body positions (including supine) to completely resolve apneas, hypopneas, and flow limitations.

Comparison of Surgical Interventions for Sleep Apnea